Prostate Cancer

New strategies in mCRPC focus on sequencing, genomics and earlier use of targeted therapies to improve outcomes for patients.

Personalized treatment, exercise and supportive care improve outcomes for patients with metastatic hormone-sensitive prostate cancer.

The CAPTAIN trial shows MRI-guided TULSA preserved erectile and urinary function versus surgery in localized prostate cancer.

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

A stage 4 prostate cancer survivor shares his story of positivity and gratitude.

An analysis found docetaxel plus ADT to be the most cost-effective therapy for HRR+ metastatic hormone-sensitive prostate cancer.

Adding cabazitaxel to hormone therapy and radiation did not improve survival and caused more side effects in high-risk localized prostate cancer.

Adding 177Lu-PSMA-617 to combination therapy improves disease control in PSMA+ mHSPC while maintaining quality of life and pain outcomes.

Adding Xofigo to Xtandi extends survival and delays disease progression in men with metastatic castration-resistant prostate cancer with bone involvement.

CAPItello-281 shows Truqap plus Zytiga extends rPFS in PTEN-deficient mHSPC with manageable toxicity and preserved overall quality of life.

Oncologists highlight key 2026 ASCO GU studies in bladder, prostate, kidney and testicular cancers that could reshape treatment and personalize care.

A PSMA PET scan found more recurrent prostate cancer at low PSA levels than a standard scan, helping guide more potentially curative treatment decisions.

Amid the grief that I have and continue to deal with due to my sister’s death from cancer, I have been blessed with phenomenal support.

The U.S. FDA granted “study may proceed” clearance for a trial of teverelix in patients with advanced prostate cancer and high cardiovascular risk.

A phase 2 trial found oxybutynin safely reduced the frequency and severity of hot flashes in men receiving hormone therapy for prostate cancer.

A real-world study found Erleada reduced the risk of death compared with Nubeqa in patients with metastatic castration-sensitive prostate cancer.

I reflect on cancer and faith, embracing the power of one to pursue health, purpose, and positive change in my life and for others.

Prostate cancer survivors Ronald Wakefield and Ernie Strauss sat down for an interview with CURE.

The FDA granted fast track designation to Enolen for patients with low-to-intermediate risk prostate cancer.

My initial reaction was fear: Fear of the unknown possibilities of what could happen as a result of this most dreaded diagnosis.

The FDA granted regular approval to treatment with Rubraca for some adult patients with previously-treated metastatic castration-resistant prostate cancer.

Newly diagnosed with stage 3 prostate adenocarcinoma? Understand your diagnosis and explore multimodality treatment options for an informed cancer journey.

The FDA approved Akeega combination therapy for adults with BRCA2-mutated metastatic castration-sensitive prostate cancer.

Among young patients, clinical trial results have shown that Pedmark is associated with a reduction in chemotherapy-induced ear damage.

Stoboclo and Osenvelt is now interchangeable with brand-name drugs, per the FDA, letting pharmacists substitute them while ensuring safety and efficacy.